FDA granted marketing approval for a new formulation of controlled-release oxycodone (OxyContin, Purdue Pharma) on April 5, 2010.
FDA granted marketing approval for a new formulation of controlled-release oxycodone (OxyContin, Purdue Pharma) on April 5, 2010. The reformulated drug is designed to help discourage misuse and abuse of the medication by preventing people from overcoming the sustained-release mechanism. For example, any attempt to dissolve the new formulation in liquid will result in a "gummy substance" that would be difficult, if not impossible, to be drawn up into a syringe and injected.
The drug is formulated to slowly release large quantities of oxycodone over an extended period of time. It is commonly used to treat patients who require continuous, around-the-clock management of sustained or chronic moderate-to-severe pain, such as patients with cancer. Unfortunately, many people were able to release most, if not all of the oxycodone from the older formulation at once. This rapid release of the potent opioid often resulted in fatal overdose and contributed to high abuse rates. In fact, a recent report from the U.S. Substance Abuse and Mental Health Services Administration estimated that approximately 500,000 people tried OxyContin for non-medical purposes in 2008.
"OxyContin now joins Embeda as opioids with tamper-resistant dosage forms," noted Richard Gannon, PharmD, a clinical pharmacist and pain management specialist for the Department of Pharmacy at Hartford Hospital in Hartford, Conn. He continued, "These new products should prevent abuse by crushing, chewing, or dissolving and injecting."
"It will be interesting to see if the post-marketing surveillance data supports their tamper-resistant contention," said Dr Gannon. "These drugs may still be abused by swallowing the tablets whole."
Bob Rappaport, MD, director of the Division of Anesthesia and Analgesia Products in FDA's Center for Drug Evaluation and Research said in an FDA press release, "Although this new formulation of OxyContin may provide only an incremental advantage over the current version of the drug, it is still a step in the right direction."
According to Dr Gannon, the best deterrent to abuse is a practitioner that appropriately evaluates a patient's pain problem and screens the patient for a history of substance abuse. Dr Gannon further emphasized, "Use of an opioid contract, urine drug screens, pill counts, and so on can be effective components of a comprehensive pain management program."
SOURCES
1. FDA. FDA Approves New Formulation for OxyContin. April 5, 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm207480.htm. Accessed April 6, 2010.
2. Substance Abuse and Mental Health Services Administration. 2009. Results from the 2008 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434) Rockville, MD. September 1, 2009. Available at: http://ncadistore.samhsa.gov/catalog/productDetails.aspx?ProductID=18177/. Accessed April 23, 2010.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.